A detailed history of Liberty One Investment Management, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Liberty One Investment Management, LLC holds 13 shares of KRYS stock, worth $2,475. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13
Previous 140 90.71%
Holding current value
$2,475
Previous $26,000 92.31%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$174.7 - $213.66 $22,186 - $27,134
-127 Reduced 90.71%
13 $2,000
Q2 2024

Jul 22, 2024

SELL
$153.12 - $183.64 $2,909 - $3,489
-19 Reduced 11.95%
140 $26,000
Q1 2024

Apr 30, 2024

BUY
$108.01 - $179.35 $864 - $1,434
8 Added 5.3%
159 $28,000
Q4 2023

Jan 26, 2024

BUY
$96.0 - $128.29 $4,992 - $6,671
52 Added 52.53%
151 $18,000
Q3 2023

Nov 03, 2023

BUY
$108.51 - $130.22 $1,085 - $1,302
10 Added 11.24%
99 $11,000
Q1 2023

May 15, 2023

BUY
$72.39 - $84.27 $6,442 - $7,500
89 New
89 $7,000
Q4 2021

Jan 21, 2022

SELL
$39.81 - $88.24 $107,367 - $237,983
-2,697 Closed
0 $0
Q3 2021

Oct 20, 2021

SELL
$52.01 - $71.77 $3,744 - $5,167
-72 Reduced 2.6%
2,697 $141,000
Q2 2021

Jul 20, 2021

BUY
$62.14 - $81.82 $41,447 - $54,573
667 Added 31.73%
2,769 $188,000
Q1 2021

Apr 06, 2021

BUY
$59.42 - $85.46 $32,383 - $46,575
545 Added 35.0%
2,102 $162,000
Q4 2020

Jan 20, 2021

BUY
$40.64 - $61.38 $21,132 - $31,917
520 Added 50.14%
1,557 $93,000
Q3 2020

Nov 03, 2020

BUY
$37.76 - $48.49 $19,899 - $25,554
527 Added 103.33%
1,037 $45,000
Q2 2020

Jul 22, 2020

BUY
$37.03 - $60.0 $18,885 - $30,600
510 New
510 $21,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.89B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Liberty One Investment Management, LLC Portfolio

Follow Liberty One Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Liberty One Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Liberty One Investment Management, LLC with notifications on news.